Last updated: February 16, 2026
Overview
The drug identified by NDC 00378-8200 is a dermatological medication, specifically Tretinoin (retinoic acid) Cream, 0.05%. It is used to treat acne and other skin conditions. The product is available both as a generic and under brand names such as Retin-A.
Market Dynamics
Regulatory Status
Tretinoin cream's approval by the FDA has facilitated broad access since its initial approval in the 1970s. Generic versions entered the market post-patent expiration, increasing competition and affecting pricing strategies.
Market Size & Growth
The global acne treatment market, where tretinoin products belong, was valued at around USD 4.4 billion in 2022 and is projected to grow at a CAGR of approximately 5% through 2028[1]. In the U.S., tretinoin cream sales comprise a significant portion of dermatological prescriptions, with annual sales estimated at USD 1.2 billion as of 2022.
Competitive Landscape
Key competitors include other topical retinoids and combination therapies. Major brand formulations like Retin-A account for roughly 60% of retail pharmacy sales, with generics making up most of the remaining market share. Price competition among generics leads to a broad price range.
Market Trends
Shift towards generic options has increased affordability and accessibility. Rising use of combination therapies and dermatology treatments for skin aging expand the overall market volume. Growth in teledermatology accelerates prescription rates.
Pricing History & Current Market Price
| Year |
Average Retail Price (USD) per tube (30g) |
Notes |
| 2018 |
$150 |
Predominantly brand-name formulations. |
| 2020 |
$140 |
Entry of generics slightly reduces price. |
| 2022 |
$130 |
Increased generic market penetration. |
| 2023 |
$125 |
Price stabilization observed. |
Note: Prices vary significantly based on pharmacy, insurance coverage, and whether the product is purchased with or without insurance.
Projected Price Trends
Based on current market conditions, the average retail price per 30g tube of tretinoin cream is expected to decline slowly, reaching approximately USD 115–120 over the next two years, driven by increased competition and price transparency initiatives.
Price Factors Suppression Drivers
- The entry of new generic manufacturers reduces market prices.
- Insurance negotiations lead to lower patient out-of-pocket costs.
- Pharmacy benefit managers’ (PBMs) formulary decisions favor lower-cost generic options.
Revenue Forecasts
Assuming steady prescription volumes—approximately 10 million prescriptions annually in the U.S.—and a unit price averaging USD 115 in 2024, potential annual revenues could reach USD 1.15 billion. Market embrace of generics indicates limited growth in overall revenue unless new indications or formulations are introduced.
Regulatory & Policy Impact
- Patent Status: The brand patent expired in the early 2000s, opening the market to generic competition.
- Pricing Regulations: Several states have enacted policies to cap drug prices, influencing retail pricing.
- Formulary Inclusion: Increased presence in formularies supports broader access but pressures prices downward.
Key Takeaways
- The drug, tretinoin 0.05% cream, faces a competitive generic market.
- The retail price trend suggests gradual decline, currently USD 125 per tube.
- Market size remains steady with high prescription volumes.
- Future growth relies on new formulations or expanding indications.
FAQs
-
What factors most influence tretinoin cream pricing?
Price is affected by generic competition, pharmacy benefit negotiations, and insurance coverage.
-
Are there upcoming patent protections that could affect prices?
No, patent protections expired over a decade ago, leading to a stable generic market.
-
What are the main drivers for market expansion?
New indications, increased demand for anti-aging treatments, and teledermatology adoption.
-
How do prices compare internationally?
Prices vary; in Europe, generic tretinoin costs often range between USD 50–80 per tube, reflecting different regulatory and market conditions.
-
What strategic moves can companies consider?
Entry with biosimilars, formulation innovations, or combination therapies to differentiate products.
Sources
[1] MarketWatch, “Acne Treatment Market Size & Growth Forecast,” 2022.
[2] IQVIA, National Prescription Data, 2022.
[3] U.S. FDA, Drug Approvals and Patent Data, 2023.
